Edition:
India

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

11.74USD
8:41pm IST
Change (% chg)

$-0.15 (-1.26%)
Prev Close
$11.89
Open
$11.79
Day's High
$11.87
Day's Low
$11.61
Volume
37,079
Avg. Vol
126,612
52-wk High
$30.25
52-wk Low
$10.29

Summary

Name Age Since Current Position

Vikram Malik

56 2018 Chairman of the Board

David Moatazedi

41 2018 President, Chief Executive Officer, Director

Lauren Silvernail

60 2018 Chief Financial Officer, Executive Vice President - Corporate Development

Michael Jafar

38 2018 Chief Marketing Officer

Alejandro Sabad

2018 Vice President - Operations

Kurt Knab

2018 Vice President of Sales

Amy Fox

2018 Vice President of Human Resources

Crystal Muilenburg

2019 Vice President, Corporate Communications and Public Relations

Rui Avelar

57 2018 Chief Medical Officer, Head of Research & Development

Simone Blank

56 2018 Director

Peter Farrell

77 2019 Independent Director

David Gill

64 2018 Independent Director

Bosun Hau

40 2018 Independent Director

Robert Hayman

60 2018 Independent Director

Karah Parschauer

41 2019 Independent Director

Kristine Romine

54 2018 Independent Director

Brian Johnston

IR Contact Officer

Biographies

Name Description

Vikram Malik

Mr. Vikram Malik is Chairman of the Board of the company since January 2018. Mr. Malik has served as a member of ALPHAEON’s board of directors since April 2014. Since May 2013, Mr. Malik has served as the Managing Partner of SCH. From August 2011 to May 2013, Mr. Malik served as Vice Chairman Investment Banking for Deutsche Bank Securities, Inc. From November 2010 to August 2011, Mr. Malik served as a Managing Director in the Healthcare Corporate and Investment Banking Group of Merrill Lynch, Pierce, Fenner & Smith Incorporated. From June 2000 to November 2010, Mr. Malik served as the Managing Director of Banc of America Securities, LLC. Mr. Malik received a B.A. in Economics from Delhi University and an M.B.A. from Boston University Graduate School of Management.

David Moatazedi

Mr. David Moatazedi is President, Chief Executive Officer, Director of the Company. He was the Senior Vice President at Allergan, Inc. (“Allergan”), and division head of the U.S. Medical Aesthetics division, which includes facial aesthetics, plastic surgery, regenerative medicine, body contouring, and skin care products from March 2016 to May 2018. Since March 2017, Mr. Moatazedi has served as a member of the board of directors of Obalon Therapeutics, Inc., a public medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Mr. Moatazedi has worked in various leadership capacities within Allergan since March 2005, including as Vice President, Sales and Marketing of the U.S. Facial Aesthetics division from August 2014 to March 2016 and Vice President, Sales and Market of the U.S. Plastic Surgery division from February 2013 to August 2014. Prior to Allergan, Mr. Moatazedi was a district manager at Novartis Pharmaceuticals for the Dermatology division. Mr. Moatazedi holds an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.

Lauren Silvernail

Mrs. Lauren P. Silvernail is Chief Financial Officer, Executive Vice President - Corporate Development of the company. She has served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. ("Revance"), a pharmaceutical research and development company, from December 2015 to May 2018 and as Revance's Chief Financial Officer and Executive Vice President, Corporate Development from March 2013 to December 2015. From 2003 to 2012, Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a pharmaceutical research and development company. From 1995 to 2003, Mrs. Silvernail served in various operating and corporate development positions with Allergan, Inc., a pharmaceutical company, including Vice President, Business Development. Prior to joining Allergan, Inc., Mrs. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and the audit committee of Nicox S.A. Mrs. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.

Michael Jafar

Mr. Michael Jafar has served as our Chief Marketing Officer of the Company since June 2018. From April 2017 to June 2018, he served as Vice President, Medical Aesthetics at Allergan. Mr. Jafar has worked in various leadership capacities within Allergan since March 2003, including as Associate Vice President, Strategic Marketing and Communications of the Medical Aesthetics division from May 2015 to April 2017 and roles as Senior Director of Marketing for aesthetic products such as SkinMedica, Latisse and Juvederm from October 2011 to May 2015. Mr. Jafar holds an M.B.A. from the University of Southern California and a B.B.A. from the University of San Diego

Alejandro Sabad

Mr. Alejandro Sabad is Vice President - Operations of the Company. Mr. Sabad brings over 25 years of combined industry & consulting experience with a range of life science companies and is recognized for his expertise in global manufacturing and operations. Mr. Sabad formerly served as a Managing Director at Deloitte Consulting where he served as the Technical Operations Solution and Global Manufacturing Strategy & Operations Lead and led the Contract Development and Manufacturing Organizations (CDMO) segment for the practice. Prior to Deloitte, he served as Vice President of Operations Strategy and Network Performance Management at MedImmune, AstraZeneca's global biologics division which contributed over $1.0 billion of annual revenue. Mr. Sabad received an MBA in Strategy & Finance from the Mendoza School of Business at the University of Notre Dame and a BA from the University of California, Los Angeles.

Kurt Knab

Mr. Kurt Knab is Vice President of Sales of the Company. Mr. Knab joins Evolus from Medline Industries where he served as Vice President of Business Development and Sales. Prior to that, Kurt spent sixteen years at LifeCell Corporation where he held various roles in sales leadership and ultimately served as Vice President, U.S. Sales for 4 years. At LifeCell he was responsible for leading the commercial efforts of the LifeCell's entire portfolio including Alloderm ® , Strattice ® , and Revolve ® . Mr. Knab has over 20 years of commercial and executive experience with top performing medical device companies. He spent the early part of his career with Pfizer and Mitek Products, an Ethicon Company, developing high growth markets. Kurt earned a BS in Marketing from Penn State University.

Amy Fox

Ms. Amy Marinne Fox is Vice President of Human Resources of the Company. Ms. Fox has over 20 years of experience building high performing, agile organizations. Ms. Fox previously served as Vice President, Human Resources of Orexigen Therapeutics, where she led the design of employee retention programs and global HR capabilities to meet organizational demands with system implementations, metrics and process improvements. Prior to Orexigen, she served as Director of Human Resources at Synteract, a global Clincal Research Organization specializing in the delivery of clinical trial solutions across multiple therapeutic areas. Previously, she served as a Human Resources Manager at Robbins Arroyo, a boutique law firm specializing in securities litigation. Ms. Fox earned a BA in Literature-Writing at the University of California San Diego.

Crystal Muilenburg

Ms. Crystal Muilenburg is Vice President, Corporate Communications and Public Relations of the company. Crystal has nearly two decades of experience in corporate communications, public relations, advocacy, society relations, strategic marketing and commercial marketing for mid-cap and start-up enterprises. Most recently, Crystal was head of global strategic marketing at Sienna Biopharmaceuticals, a clinical-stage medical dermatology company, where she also supported the company's corporate branding and corporate communications activities. Prior to Sienna, Crystal spent more than a decade at Allergan serving in various leadership positions in corporate communications and public relations and U.S. and international marketing, specifically in medical aesthetics, where she built a deep expertise in brand awareness and consumer activation strategies while marketing directly to women and influencers. Crystal earned a B.S. degree in Biology from California Polytechnic State University, San Luis Obispo.

Rui Avelar

Dr. Rui Avelar, M.D., is Chief Medical Officer, Head of Research & Development of the Company. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.

Simone Blank

Ms. Simone Blank is Director of the company since January 2018. Ms. Blank has served as the chairman of the board of directors of ALPHAEON since July 2016. Ms. Blank is also the co-owner of Dental Innovations BVBA, the collateral agent for the holders of the convertible promissory notes issued by ALPHAEON. Since 2013, Ms. Blank has served as a member of the board of directors of several private healthcare companies. From May 2006 to October 2013, Ms. Blank served as a member of the board of directors of Sirona Dental Systems Inc., or Sirona, a dental technology manufacturer previously listed on Nasdaq. From July 1999 to October 2013, Ms. Blank served as Executive Vice President and Chief Financial Officer of Sirona. Prior to July 1999, Ms. Blank was an engagement manager in the merger and acquisition transaction group of PricewaterhouseCoopers after having gained global financial experience as a certified public accountant and tax advisor. Ms. Blank received a M.Sc. in Economics from the University of Duisburg, Germany.

Peter Farrell

Dr. Peter C. Farrell, Ph.D. is Independent Director of the Company. He is an industry veteran with extensive public company experience having successfully taken companies from inception through full scale commercialization. He is the Founder and current Chairman of the Board of ResMed (NYSE: RMD) (ASX: RMD), where he served as its Chief Executive Officer until 2014. Prior to founding ResMed, Dr. Farrell served as Vice President, Research and Development at various subsidiaries of Baxter International, Inc. and served as Managing Director of the Baxter Center for Medical Research Pty Ltd, a Baxter subsidiary. He previously served as Foundation Director of the Graduate School for Biomedical Engineering at the University of New South Wales where he currently serves as a Visiting Professor. Dr. Farrell is on the Visiting Committee of the Harvard/MIT Health Sciences & Technology Program and currently serves on the MIT Dean of Engineering's Advisory Council. Dr. Farrell is on the board of Arcturus Therapeutics Ltd (NASDAQ: ARCT), serves as the Chairman of WaveGuide and was previously a director of NuVasive, Inc. (NASDAQ: NUVA). Dr. Farrell holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington Seattle and a D.Sc. from the University of New South Wales.

David Gill

Mr. David N. Gill serves as Independent Director of the company. Mr. Gill has served as a member of the board of directors and audit committee chairman of Y-mAbs Therapeutics, Inc. since December 2017. Mr. Gill has served as a member of the board of directors and audit committee chairman of Histogenics Corporation since 2015. Since 2012, Mr. Gill has also served as a member of the board of directors and audit committee chairman of Melinta Therapeutics (formerly known as Cempra, Inc.). From May to November 2015, Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease. Mr. Gill joined EndoChoice, Inc. as Chief Financial Officer in August 2013 and was subsequently appointed President in 2015. From February 2011 to August 2013, he served as the Chief Financial Officer of INC Research, a clinical research organization. Mr. Gill holds a B.S. degree in Accounting from Wake Forest University and an M.B.A. degree from Emory University, and was formerly a certified public accountant.

Bosun Hau

Mr. Bosun S. Hau is Independent Director of the company since January 2018. Mr. Hau has served as a member of ALPHAEON’s board of directors since May 2016. Since October 2015, Mr. Hau has served as a Managing Director and Partner of Sailing Capital. From August 2009 to October 2015, Mr. Hau served as a Partner of MVM Life Science Partners LLP. From July 2004 to August 2007, Mr. Hau served as an equity research analyst covering the medical device and pharmaceutical industries for JP Morgan Securities, Inc. and Prudential Securities, Inc. Since 2009, Mr. Hau has served as a member of the board of directors of several private biotechnology, specialty pharmaceutical and medical device companies. Mr. Hau received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and a B.A. in Psychology from the University of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University and an M.B.A in Finance and Health Management from the Wharton School at the University of Pennsylvania.

Robert Hayman

Mr. Robert Hayman is Independent Director of the company since January 2018. Mr. Hayman served as a member of ALPHAEON’s board of directors since April 2014. Since 2011, Mr. Hayman has served as the owner and Chief Executive Officer of Hayman Properties, a real estate investment and development business. Since 2015, Mr. Hayman has served as Principal and Chief Executive Officer of Perimetrics, LLC, a dental diagnostic service company. Since April 2008, Mr. Hayman served as Principal at Common Sense Concepts, LLC, a dental device development company. From 1993 to February 2008, Mr. Hayman served as the co-founder, Chief Executive Officer and Chairman of Discus Dental, Inc. Mr. Hayman attended the masters degree program in Psychology at Pepperdine University, and received a B.S. in Business Administration from Boston University.

Karah Parschauer

Ms. Karah Parschauer, J.D. is Independent Director of the Company. She has extensive experience leading biotech companies through various phases of growth and transformation. Ms. Parschauer is currently Executive Vice President, General Counsel and Secretary to the Board of Directors at Ultragenyx Pharmaceutical (NASDAQ: RARE), a commercial stage biotechnology company focused on the treatment of rare genetic diseases, where she leads the Company's legal, compliance and government affairs departments. Prior to Ultragenyx, Ms. Parschauer was a senior leader at Allergan for 11 years, most recently as the head of legal and compliance for Allergan's Medical Aesthetic division. Ms. Parschauer currently serves on the board of Arcturus Therapeutics Ltd (NASDAQ: ARCT). Ms. Parschauer graduated from Miami University in Oxford, OH, and earned a J.D. from Harvard Law School.

Kristine Romine

Dr. Kristine Romine, M.D., is Independent Director of the company since January 2018. Dr. Romine has served as a member of ALPHAEON’s board of directors since April 2017 and will resign from ALPHAEON upon the consummation of this offering. In July 2003, Dr. Romine founded and has since served as the Chief Executive Officer of Camelback Dermatology & Skin Surgery in Phoenix, Arizona. Dr. Romine holds a B.S. degree in Biology from the University of Arizona and a M.D. from the Medical College of Wisconsin.

Brian Johnston

Basic Compensation